116 related articles for article (PubMed ID: 26637771)
21. Expression of CD30 as a biomarker to predict response to brentuximab vedotin.
Xu ML; Acevedo-Gadea C; Seropian S; Katz SG
Histopathology; 2016 Jul; 69(1):155-8. PubMed ID: 26648051
[No Abstract] [Full Text] [Related]
22. Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease.
Broccoli A; Argnani L; Zinzani PL
Cancer Treat Rev; 2017 Nov; 60():120-129. PubMed ID: 28946015
[TBL] [Abstract][Full Text] [Related]
23. Which therapies will move to the front line for multiple myeloma?
Cejalvo MJ; de la Rubia J
Expert Rev Hematol; 2017 May; 10(5):383-392. PubMed ID: 28388244
[TBL] [Abstract][Full Text] [Related]
24. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study.
Dupuis J; Morschhauser F; Ghesquières H; Tilly H; Casasnovas O; Thieblemont C; Ribrag V; Bossard C; Le Bras F; Bachy E; Hivert B; Nicolas-Virelizier E; Jardin F; Bastie JN; Amorim S; Lazarovici J; Martin A; Coiffier B
Lancet Haematol; 2015 Apr; 2(4):e160-5. PubMed ID: 26687958
[TBL] [Abstract][Full Text] [Related]
25. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Connors JM; Jurczak W; Straus DJ; Ansell SM; Kim WS; Gallamini A; Younes A; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Oki Y; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Chen R; Ramchandren R; Zinzani PL; Cunningham D; Rosta A; Josephson NC; Song E; Sachs J; Liu R; Jolin HA; Huebner D; Radford J;
N Engl J Med; 2018 Jan; 378(4):331-344. PubMed ID: 29224502
[TBL] [Abstract][Full Text] [Related]
26. Cost-utility analysis of pralatrexate for relapsed or refractory peripheral T-cell lymphoma based on a case-matched historical control study along with single arm clinical trial.
Park S; Kim AY; Cho H; Baik D; Lee H; Cho S; Kang HY
BMC Cancer; 2020 Nov; 20(1):1157. PubMed ID: 33243162
[TBL] [Abstract][Full Text] [Related]
27. [Clinical outcomes of peripheral blood stem cell transplantation for aggressive peripheral T-cell lymphoma].
Huang WR; Gu ZY; Li HH; Bo J; Wang SH; Li F; Gao XN; Dou LP; Zhao Y; Jing Y; Zhu HY; Wang QS; Yu L; Gao CJ; Liu DH
Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):729-733. PubMed ID: 30369182
[No Abstract] [Full Text] [Related]
28. New developments in immunotherapy for lymphoma.
Heyman B; Yang Y
Cancer Biol Med; 2018 Aug; 15(3):189-209. PubMed ID: 30197788
[TBL] [Abstract][Full Text] [Related]
29. Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.
Broccoli A; Pellegrini C; Di Rocco A; Puccini B; Patti C; Gini G; Mannina D; Tani M; Rusconi C; Romano A; Vanazzi A; Botto B; Carlo-Stella C; Hohaus S; Musto P; Mazza P; Molica S; Corradini P; Fama A; Gaudio F; Merli M; Gravetti A; Gritti G; Arcari A; Tosi P; Liberati AM; Pinto A; Pavone V; Gherlinzoni F; Naso V; Volpetti S; Trentin L; Goldaniga MC; Bonfichi M; De Renzo A; Schiavotto C; Spina M; Storti S; Carella AM; Stefoni V; Argnani L; Zinzani PL
Haematologica; 2017 Nov; 102(11):1931-1935. PubMed ID: 28775121
[TBL] [Abstract][Full Text] [Related]
30. Clinical features and treatment outcome of Epstein-Barr virus-positive nodal T-cell lymphoma.
Jung KS; Cho SH; Kim SJ; Ko YH; Kim WS
Int J Hematol; 2016 Nov; 104(5):591-595. PubMed ID: 27456462
[TBL] [Abstract][Full Text] [Related]
31. Bone Marrow Transplantation for Peripheral T-Cell Non-Hodgkins' Lymphoma in First Remission.
Sharma M; Pro B
Curr Treat Options Oncol; 2015 Jul; 16(7):34. PubMed ID: 26076798
[TBL] [Abstract][Full Text] [Related]
32. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
Advani RH; Ansell SM; Lechowicz MJ; Beaven AW; Loberiza F; Carson KR; Evens AM; Foss F; Horwitz S; Pro B; Pinter-Brown LC; Smith SM; Shustov AR; Savage KJ; Vose JM
Br J Haematol; 2016 Feb; 172(4):535-44. PubMed ID: 26627450
[TBL] [Abstract][Full Text] [Related]
33. Peripheral T-cell lymphoma, NOS, and anaplastic large cell lymphoma.
Beaven AW; Diehl LF
Hematology Am Soc Hematol Educ Program; 2015; 2015():550-8. PubMed ID: 26637771
[TBL] [Abstract][Full Text] [Related]
34. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
35. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
Oregel KZ; Everett E; Zhang X; Nagaraj G
Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
[TBL] [Abstract][Full Text] [Related]
36. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
Gkotzamanidou M; Papadimitriou CA
Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
